LEX
Resources
Lex by email
Sign up
FT.com subscribers can now receive three email packages: Lex live, Lex alerts and Best of Lex
Principal content
Merck / Sanofi-Aventis
The $16.5bn merger of the companies’ veterinary businesses will create the world leader in medical care for animals
Pfizer / Ratiopharm
Once a dirty word, generics is entering the vocabulary of some of the world’s largest research-led drugmakers
Astellas / OSI
The market’s initial response when Japan’s Astellas Pharma made an unsolicited $3.5bn cash offer for OSI Pharmaceuticals of the US was to send the target’s shares soaring 9 per cent above an offer already 40 per cent higher than its price on Friday
Wockhardt in India
The company is proving to be a bitter pill for foreign investors
Merck KGaA
A finger-in-the-wind growth estimate, combined with a dividend down one third on last year, left investors unimpressed
Pharming it out
Farming out a research function for pharmaceutical companies is a risky move
Pfizer pfalters
World’s largest drugmaker finds cutting costs easier than generating growth as patent on blockbuster nears expiry
Novartis
The incoming chief executive has previously advocated a steady-as-she-goes strategy but he may have cost cuts on the agenda
Insurers get Mass reprieve
Republican win in Democrats’ heartland spurs healthcare relief rally, as health insurers Humana and Aetna rally as much as 8 and 6 per cent
Novartis / Alcon
Only six months ago, Novartis’ chief executive had second thoughts about taking control of Alcon. Come the New Year, and he has changed his mind
